12:00 AM
Jun 25, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CellSearch Circulating Tumor Cell Kit diagnostic data

Researchers at the University of Texas MD Anderson Cancer Center reported data from 302 chemotherapy-naïve patients with stage I-III non-metastatic operable breast cancer showing that detection of >=1 CTC as measured by Veridex LLC's CellSearch Circulating Tumor Cell Kit predicted reductions in both PFS and...

Read the full 213 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >